Literature DB >> 12399239

The challenge of developing a vaccine against hepatitis C virus.

Xavier Forns1, Jens Bukh, Robert H Purcell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12399239     DOI： 10.1016/s0168-8278(02)00308-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  23 in total

1.  Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.

Authors:  Josep M Llovet; Anna Lok
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

2.  Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.

Authors:  Jannick Prentoe; Rodrigo Velázquez-Moctezuma; Steven K H Foung; Mansun Law; Jens Bukh
Journal:  Hepatology       Date:  2016-08-09       Impact factor: 17.425

3.  Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Authors:  Jonathan Filskov; Marianne Mikkelsen; Paul R Hansen; Jan P Christensen; Allan R Thomsen; Peter Andersen; Jens Bukh; Else Marie Agger
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 5.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

6.  NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system.

Authors:  Agnieszka Gozdek; Igor Zhukov; Agnieszka Polkowska; Jaroslaw Poznanski; Anna Stankiewicz-Drogon; Jerzy M Pawlowicz; Wlodzimierz Zagórski-Ostoja; Peter Borowski; Anna M Boguszewska-Chachulska
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

7.  Kinetics of protective antibodies are determined by the viral surface antigen.

Authors:  Daniel D Pinschewer; Mar Perez; Eswaraka Jeetendra; Thomas Bächi; Edit Horvath; Hans Hengartner; Michael A Whitt; Juan Carlos de la Torre; Rolf M Zinkernagel
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays.

Authors:  Ronald E Engle; Rodney S Russell; Robert H Purcell; Jens Bukh
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

Review 9.  Development of hepatitis C virus vaccines: challenges and progress.

Authors:  Françoise Stoll-Keller; Heidi Barth; Samira Fafi-Kremer; Mirjam B Zeisel; Thomas F Baumert
Journal:  Expert Rev Vaccines       Date:  2009-03       Impact factor: 5.217

10.  Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain.

Authors:  Jens Bukh; Robert Thimme; Jean-Christophe Meunier; Kristina Faulk; Hans Christian Spangenberg; Kyong-Mi Chang; William Satterfield; Francis V Chisari; Robert H Purcell
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.